PASC

Six long COVID subtypes identified at The Jackson Laboratory

Retrieved on: 
Friday, January 27, 2023
Ontology, Patient, HPO, EHR, Collection, COVID, SARS-CoV-2, Diagnosis, PASC, Human Phenotype Ontology, Hospital, COVID-19, Risk, Therapy, Vertigo, Database, NIH, Robinson, Predoctoral fellow, Jackson Laboratory, Phenome-wide association study, Infection, Multimedia, Research, Pharmaceutical industry

Like primary COVID-19, the affliction, known as post-acute sequelae of SARS-CoV-2 (PASC) or long COVID, has highly variable duration, symptoms and severity.

Key Points: 
  • Like primary COVID-19, the affliction, known as post-acute sequelae of SARS-CoV-2 (PASC) or long COVID, has highly variable duration, symptoms and severity.
  • Jackson Laboratory Professor Peter Robinson , M.D., M.Sc., and Predoctoral Associate Ben Coleman have been investigating long COVID using EHR data from healthcare systems across the United States as part of the National COVID Cohort Collaborative (N3C).
  • Their findings, presented in "Generalisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes" and published in eBioMedicine , indicate that long COVID does indeed manifest in distinct subtypes that can help stratify patients and inform treatment strategies.
  • And moving forward, stratifying long COVID patients will be important for effective treatment, as it is doubtful that any single approach will generalize well across the subtypes.

Solve M.E. Awarded Grant From Chan Zuckerberg Initiative to Support Patient Engagement in Long Covid Research

Retrieved on: 
Tuesday, December 13, 2022
PASC, Trust, Publication, COVID-19, COVID-19 policy of the Joe Biden administration, Food, Survivor, Human, Government, Chan Zuckerberg Initiative, Research, Patient, Curriculum, Myalgia, Solve, Knowledge, Disease, FDA, Drug development, Caregiver, Education, CZI, Food and Drug Administration Amendments Act of 2007, ME/CFS, M.E, Solve ME/CFS Initiative, Pharmaceutical industry, Long COVID, Science

LOS ANGELES, Dec. 13, 2022 /PRNewswire/ -- Today, Solve M.E. announced it is the recipient of significant grant funding from the Chan Zuckerberg Initiative (CZI). With the $247,500 in funding, Solve M.E. will develop a groundbreaking program that will train a network of patient leaders, scientists and other stakeholders with diverse backgrounds to enhance patient engagement in Long Covid research. These trained patient representatives will ultimately create a targeted research agenda, a network of empowered patient-advocates and a guide to working with Long Covid patients for researchers. These critical tools will provide urgently needed guidance on achieving patient-centered research in the Long Covid field, as well as help to empower communities in other related fields.

Key Points: 
  • will develop a groundbreaking program that will train a network of patient leaders, scientists and other stakeholders with diverse backgrounds to enhance patient engagement in Long Covid research.
  • These trained patient representatives will ultimately create a targeted research agenda, a network of empowered patient-advocates and a guide to working with Long Covid patients for researchers.
  • In key publications, like the National Research Action Plan on Long Covid 3and the recent Health+ Long Covid report 4, patient contributions have been vital.
  • to solve Long Covid and associated conditions, as well as participating in research and joining in advocacy and awareness efforts.

University of California Health launches Long COVID education series to expand access to care

Retrieved on: 
Friday, December 2, 2022
Accreditation Council for Continuing Medical Education, Knowledge, Rheumatology, COVID-19, Emergency medicine, MPH, FACOG, Pediatrics, University, Health, News, University of California, San Diego, Research, University of California, Davis, AMA, Accreditation Council, Faculty, Continuing medical education, Patient, PASC, UCLA, UCSF, Neurology, Hospital, Physician, Education, David Geffen School of Medicine at UCLA, Accreditation, UC, UCI, CME, Timeline of the COVID-19 pandemic, Cardiology, Medicine, Pharmaceutical industry

OAKLAND, Calif., Dec. 2, 2022 /PRNewswire-PRWeb/ -- University of California Health has created a video education series to inform and educate health care providers about best practices and the latest research on screening, managing symptoms and making specialty referrals for patients with post-COVID symptoms.

Key Points: 
  • OAKLAND, Calif., Dec. 2, 2022 /PRNewswire-PRWeb/ -- University of California Health has created a video education series to inform and educate health care providers about best practices and the latest research on screening, managing symptoms and making specialty referrals for patients with post-COVID symptoms.
  • The COVID-19 pandemic has been a mass disabling event that has led to long-term consequences for patients, health care providers, and the nation's system of health care, especially in medically underserved communities.
  • "By educating, equipping, and empowering more providers in the battle against the very real impact of Long COVID, we are helping expand access to care for this condition."
  • University of California Health comprises six academic health centers, 20 health professional schools, a Global Health Institute and systemwide services that improve the health of patients and the University's students, faculty, and employees.

Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Retrieved on: 
Tuesday, November 29, 2022
Health, FDA, COVID-19, General Health, Clinical Trials, Pharmaceutical, Biotechnology, COVID-19, Real estate, BHC, Diagnosis, Metal, Attention, Agriculture, Conditional sentence, Long COVID, Center of excellence, Pain, Indian stock exchange, Therapy, Valaciclovir, Fibromyalgia, Sleep, Fatigue, Perpetual Real Estate Services, Inc. v. Michaelson Properties, Inc., Financial services, FM, Anxiety, Consumer, Planet, Publishing, News, Functional somatic syndrome, Short bowel syndrome, Celecoxib, Famciclovir, PASC, Chronic fatigue syndrome, FDA, Simplex, Pharmaceutical industry, Health care, Mining

Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Key Points: 
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).
  • Planet MicroCap is a global multimedia and publishing financial news investor portal specifically focused on covering the MicroCap market by providing news, insights, education tools and expert commentary.
  • The Planet MicroCap Showcase will take place virtually, featuring 50+ companies, buy-side and sell-side analysts, wealth managers, institutional investors, family offices, hedge fund managers, retail investors and others.
  • Sectors Participating: Agriculture, Biopharma, Consumer, Energy, Financial Services, Healthcare, Industrials, Materials, Metals and Mining, Real Estate, Services, and Technology.

GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, Infectious Diseases, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Pays de Herve, Amyotrophic lateral sclerosis, Geneva University Hospitals, ALS, Patent, Patient, DNA, PASC, MS, Degenerative disease, Centre hospitalier, Multiple sclerosis, COVID-19, Euronext Paris, Pharmaceutical industry, Kantonsspital St. Gallen

GeNeuros mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.

Key Points: 
  • GeNeuros mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.
  • It has rights to 17 patent families protecting its technology.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005201/en/

GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab

Retrieved on: 
Wednesday, November 16, 2022
Health, Infectious Diseases, Hospitals, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Pays de Herve, Amyotrophic lateral sclerosis, Geneva University Hospitals, ALS, Patent, Patient, DNA, PASC, MS, Degenerative disease, Centre hospitalier, Multiple sclerosis, COVID-19, Euronext Paris, Pharmaceutical industry, Kantonsspital St. Gallen

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic (lead centre), as well as in all the other Swiss clinical centres participating to the study, i.e., Inselspital in Bern, REHAB Basel, Kantonsspital Graubnden in Chur and the Centre Hospitalier du Valais Romand in Sion (for more information, please refer to clinical trials.gov or to GeNeuros web site).

Key Points: 
  • GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic (lead centre), as well as in all the other Swiss clinical centres participating to the study, i.e., Inselspital in Bern, REHAB Basel, Kantonsspital Graubnden in Chur and the Centre Hospitalier du Valais Romand in Sion (for more information, please refer to clinical trials.gov or to GeNeuros web site).
  • GeNeuros mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by human endogenous retroviruses (HERVs), which represent 8% of human DNA.
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.
  • It has rights to 17 patent families protecting its technology.

Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022
COVID-19, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, FDA, Center of excellence, Communication, Advertising, Clinical trial, Anxiety, Grammatical mood, Valaciclovir, Simplex, Environment, Fibromyalgia, Functional somatic syndrome, Drug development, Therapy, Database, Short bowel syndrome, Famciclovir, Patient, Conference, Attention, PASC, Doctor of Philosophy, Fatigue, Vaccination, COVID, FM, Research, Depression, Chronic fatigue syndrome, Celecoxib, Sleep, Pain, Conditional sentence, COVID-19, Diagnosis, COVID-19 testing, BHC, Webcast, Pharmaceutical industry, MD

Research and development expenses for the third quarter ended September 30, 2022 were $1.6 million, compared to $3.0 million for the third quarter ended September 30, 2021.

Key Points: 
  • Research and development expenses for the third quarter ended September 30, 2022 were $1.6 million, compared to $3.0 million for the third quarter ended September 30, 2021.
  • General and administrative expenses for the third quarter ended September 30, 2022 were $0.9 million, compared to $1.1 million for the third quarter ended September 30, 2021.
  • Virios Therapeutics management will host a webcast and conference call on November 14, 2022, at 8:30 a.m.
  • ET to discuss the Companys financial results and provide a corporate update.

Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Company, Center of excellence, Fatigue, Simplex, Fibromyalgia, Celecoxib, FDA, Investor, Webcast, Functional somatic syndrome, PASC, Short bowel syndrome, COVID-19, Therapy, Nasdaq, Attention, Famciclovir, Sleep, Conditional sentence, Anxiety, FM, Valaciclovir, Center, Chronic fatigue syndrome, Diagnosis, Pain, BHC, Pharmaceutical industry

Management will also host a webcast and conference call on November 14, 2022 at 8:30 a.m.

Key Points: 
  • Management will also host a webcast and conference call on November 14, 2022 at 8:30 a.m.
  • ET to discuss the results and provide a corporate update.
  • The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations .
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Pediatric and Autonomic Dysfunction Long COVID Symptoms Guidance Statements Released by the American Academy of Physical Medicine and Rehabilitation

Retrieved on: 
Wednesday, September 28, 2022
American Academy, Symptoms of COVID-19, PM, Pediatrics, Muscle, COVID-19, Blood pressure, Spinal cord, PASC, Brain, Autonomic nervous system, Association of Academic Physiatrists, Perspiration, Headache, Digestion, AAPM, PM&R, COVID, Patient, Mental health, Physician, Quality of life, Injury, AAPM&R, Respiration, Ligament, Heart rate, Dysautonomia, Anxiety, Diagnosis, Caregiver, Neurology, Tendon, Parent, Fever, Fatigue, R, Joint, American Academy of Physical Medicine and Rehabilitation, Kennedy Krieger Institute, Depression, Physical medicine and rehabilitation, Pharmaceutical industry, Residential care, MD, Long COVID, Rehabilitation

ROSEMONT, Ill., Sept. 28, 2022 /PRNewswire/ -- Today, the American Academy of Physical Medicine and Rehabilitation (AAPM&R) announced new guidance for diagnosing and treating pediatric patients with Long COVID symptoms and patients with autonomic dysfunction symptoms of Long COVID.

Key Points: 
  • ROSEMONT, Ill., Sept. 28, 2022 /PRNewswire/ -- Today, the American Academy of Physical Medicine and Rehabilitation (AAPM&R) announced new guidance for diagnosing and treating pediatric patients with Long COVID symptoms and patients with autonomic dysfunction symptoms of Long COVID.
  • These statements are part of a multidisciplinary collaborative consensus guidance series for the most predominant Long COVID symptoms.
  • Patients with autonomic dysfunction due to Long COVID may have difficulty remaining upright or standing without experiencing symptoms.
  • The American Academy of Physical Medicine and Rehabilitation is the national medical specialty organization representing more than 10,000 physicians specializing in physical medicine and rehabilitation.

Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Retrieved on: 
Monday, September 19, 2022
Research, Women, FDA, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Celecoxib, BHC, COVID-19, Sleep, Short bowel syndrome, American College, PASC, FDA, Center, ID, Week, Vaccination, Company, Fibromyalgia, Functional somatic syndrome, American College of Rheumatology, Therapy, Valaciclovir, Famciclovir, Patient, Attention, Chronic fatigue syndrome, CEO, Pain, Female, Numerical, Nasdaq, Omicron, Anxiety, Diagnosis, Center of excellence, Simplex, Fatigue, FM, Conditional sentence, Pharmaceutical industry, Medical device, Delta

The Virios Therapeutics team received unblinded data relating to the FORTRESS study on Friday, September 16, 2022.

Key Points: 
  • The Virios Therapeutics team received unblinded data relating to the FORTRESS study on Friday, September 16, 2022.
  • Virios Therapeutics will host a conference call and live webcast to discuss the FORTRESS study results today, Monday, September 19th, at 8:30 a.m. Eastern Time.
  • A live webcast and replay of the call will also be available on the Virios Therapeutics, Inc. website at www.virios.com .
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).